• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
BNGO

BNGO

Bionano Genomics, Inc.

NASDAQHealthcareMedical - Diagnostics & ResearchUS

USD1.30

+0.04 (+3.17%)

Rating:B-

Company Profile

CEO

Robert Erik Holmlin

IPO Date

2018-08-21

Sector

Healthcare

Industry

Medical - Diagnostics & Research

Exchange

NASDAQ

Country

US

Market Metrics

Open

$1.26

Prev. Close

$1.26

Day Low

$1.23

Day High

$1.37

52W Low

$1.06

52W High

$5.50

Market Cap

$0.00B

Volume

0.25M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

34.9%

Avg Negative

4.0%

Avg Neutral

61.4%

News Feed

The Price Is Right for BioNano Genomics Given Saphyr's Potential

InvestorPlace·8/30/2021·↑ positive

Bionano Stock Will Soar as the Company's Diagnostic System Catches On

InvestorPlace·8/18/2021·↑ positive

Faster and Better Clinical Outcomes Make the Case for Bionano Genomics

InvestorPlace·8/5/2021·↑ positive

Bionano Genomics' (BNGO) CEO Erik Holmlin on Q2 2021 Results - Earnings Call Transcript

Seeking Alpha·8/4/2021·↓ negative

Bionano Genomics, Inc. (BNGO) Reports Q2 Loss, Tops Revenue Estimates

Zacks Investment Research·8/4/2021·↑ positive

Bionano Genomics Reports Second Quarter 2021 Financial Results and Highlights Recent Business Progress

GlobeNewsWire·8/4/2021·↑ positive

Bionano's Technology Is Interesting, But Its Earnings Are Uninspiring

InvestorPlace·8/2/2021·↑ positive

Bionano (BNGO) to Report Q2 Earnings: What's in the Cards?

Zacks Investment Research·7/29/2021·↑ positive

Bionano Genomics to Report Second Quarter 2021 Financial Results and Host a Conference Call and Webcast on August 4, 2021

GlobeNewsWire·7/28/2021·↑ positive

Weak Fundamentals Prove There Is No Reason to Buy Bionano Genomics

InvestorPlace·7/23/2021·↓ negative